EMA Panel Recommends Baxfendy for Hard-to-Control Hypertension

EMA Panel Recommends Baxfendy for Hard-to-Control Hypertension

Baxfendy is poised to become the European Union’s first approved aldosterone synthase inhibitor after winning a key recommendation from the European Medicines Agency to treat hard-to-control arterial hypertension. What it … Read More